Drugs / AUX-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06249581 | Nov 2023 → Feb 2024 | intermediate coronary syndrome | Auxilius Pharma sp.z.o.o. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2024-09-02 | Auxilius Pharma sp.z.o.o. | Results AUX-001 Phase 1a results presented at European Society of Cardiology annual meeting 2024 auxiliuspharma.com ↗
AUX-001 Phase 1a results presented at European Society of Cardiology annual meeting in London by Uwe Tigör, MD, our Chief Medical Officer at Auxilius Pharma. |
| 2024-06-05 | Auxilius Pharma sp.z.o.o. | Results CSAP Management: Uwe P Tigör from Auxilius Pharma in Conversation with PharmaShots auxiliuspharma.com ↗
Today at PharmaShots we have Uwe P Tigör, Co-founder and Chief Medical Officer at Auxilius Pharma, shedding light on the positive results from Ph1a study evaluating AUX-001 for treating regular chronic stable angina pectoris (CSAP) |
| 2024-03-27 | Auxilius Pharma sp.z.o.o. | Regulatory Auxilius Pharma to launch Phase 1b anti-anginal trial after IND application auxiliuspharma.com ↗
Auxilius Pharma will be submitting an investigative new drug (IND) application for AUX-001 with plans to initiate a Phase Ib trial in chronic stable angina pectoris (CSAP). |
| 2024-03-15 | Auxilius Pharma sp.z.o.o. | Results Media Release: Pioneering Progress: Auxilius Pharma's AUX-001 Delivers Positive First-in-Human Pharmacokinetic & Safety Results in Anti-Anginal R&D auxiliuspharma.com ↗
The study's topline results showed that AUX-001 effectively extended the half-life of nicorandil from the standard 49±8 min , as seen with the current immediate-release form administered twice daily, to over 9 hours. |
| 2024-03-15 | Auxilius Pharma sp.z.o.o. | Results FirstWord Pharma: Pioneering Progress, Auxilius Pharma's AUX-001 Delivers Impressive First-in-Human Pharmacokinetic and Safety Results in Anti-Anginal R&D auxiliuspharma.com ↗
The study's topline results showed that AUX-001 effectively extended the half-life of nicorandil from the standard 49 ± 8 min, as seen with the current immediate-release form administered twice daily, to over 9 hours. |
| 2024-03-15 | Auxilius Pharma sp.z.o.o. | Results Angina: Auxilius Pharma Announces Successful Conclusion of First-in-Human Clinical Trial of AUX-001 for Treatment of Chronic Stable Angina Pectoris auxiliuspharma.com ↗
The study's topline results showed that AUX-001 effectively extended the half-life of nicorandil from the standard 49±8 min, as seen with the current immediate-release form administered twice daily, to over 9 hours. |
All press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUX-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06249581 ↗ |
| Known as | nicorandil | “AUX-001 (extended-release nicorandil) 40mg QD (once-daily)” NCT06249581 ↗ |
| Route | Oral | “orally administered AUX-001” NCT06249581 ↗ |